Theralase Technologies (CVE:TLT) Shares Down 7.4% – Here’s What Happened

Theralase Technologies Inc. (CVE:TLT)’s stock price fell 7.4% on Friday . The company traded as low as C$0.23 and last traded at C$0.25. 287,012 shares traded hands during trading, an increase of 141% from the average session volume of 119,241 shares. The stock had previously closed at C$0.27.

Theralase Technologies Price Performance

The company’s 50-day simple moving average is C$0.27 and its 200-day simple moving average is C$0.21. The company has a debt-to-equity ratio of 20.58, a quick ratio of 3.40 and a current ratio of 1.21. The company has a market capitalization of C$61.39 million, a PE ratio of -12.50 and a beta of 1.36.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.